US EditionFull-Spectrum CBD Drug for Autism Spectrum Disorder Poised for Phase 2 Clinical Trials in the US - Business of Cannabis
Summary by Business of Cannabis
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Full-Spectrum CBD Drug for Autism Spectrum Disorder Poised for Phase 2 Clinical Trials in the US - Business of Cannabis
DeFloria, a joint venture between Charlotte’s Web Holdings and Ajna BioSciences, is advancing toward the start of its Phase 2 clinical trial for AJA001, a cannabinoid-based (FDA) botanical drug developed to treat behavioural symptoms associated with autism spectrum disorder (ASD). In February 2025, the company announced that its Investigational New Drug (IND) application for Phase 2 clinical trials had been cleared by the FDA, marking the first …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
